Four children (3 boys) aged 11.6 to 13.7 years were treated with SSRIs for obsessive-compulsive disorder or Tourette syndrome. The height of the patients and their parents was measured with a stadiometer (Harpenden; Holtain Ltd, Crymych, Wales), and growth velocity was calculated during 6-month intervals. Auxologic results were expressed in terms of SD score (SDS) for age, based on the standards of Tanner and Whitehouse.15 Puberty was assessed according to Marshall and Tanner16,17 and bone age according to Greulich and Pyle.18 Target height was determined according to midparental height corrected for sex, by means of standard equations.19 The GH stimulation tests were performed after priming with estrogen (ethynylestradiol, 40 µg/m2 per day for 2 days before testing).20 The clonidine hydrochloride test was performed with a single oral dose of clonidine hydrochloride (Normopresan; Rafa, Jerusalem, Israel), 150 µg/m2, and blood samples were drawn at 0, 30, 60, 90, and 120 minutes for GH determination. The glucagon stimulation test was performed with an intramuscular injection of glucagon, 30 µg/kg (maximum, 1 mg) (Novo Nordisk, Bagsvaerd, Denmark), and blood samples were drawn at 0, 120, 180, and 240 minutes. Pass levels were defined as a peak GH level of 10 ng/mL (440 pmol/L) or greater. To determine 24-hour integrated concentration of GH, blood was obtained every 30 minutes with a nonthrombogenic continuous withdrawal pump.21 The serum GH, prolactin, cortisol, and free thyroxine concentrations were determined with a commercially available solid-phase chemiluminescent enzyme immunoassay; thyrotropin concentration, with an immunometric assay that used an automated analyzer (Immulite; Diagnostic Products Corporation, Los Angeles, Calif); and 24-hour urinary free cortisol excretion with radioimmunoassay (Diagnostic Products Corporation).